Published in Mol Neurobiol on September 04, 2012
Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med (2013) 1.02
Alpha-synuclein as a pathological link between chronic traumatic brain injury and Parkinson's disease. J Cell Physiol (2015) 0.96
Preparation and Characterization of Stable α-Synuclein Lipoprotein Particles. J Biol Chem (2016) 0.80
Traumatic Brain Injury Leads to Development of Parkinson's Disease Related Pathology in Mice. Front Neurosci (2016) 0.77
Alpha-synuclein levels in blood plasma decline with healthy aging. PLoS One (2015) 0.77
α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology. J Neuroinflammation (2016) 0.75
The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy. Neural Plast (2017) 0.75
Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson's disease? Acta Neuropathol Commun (2017) 0.75
The Chemical Molecule B355252 is Neuroprotective in an In Vitro Model of Parkinson's Disease. Cell Mol Neurobiol (2015) 0.75
Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurobiol Dis (2002) 2.83
Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci (2007) 2.28
The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and alpha-synuclein. J Biol Chem (2001) 1.99
Lysosomal degradation of alpha-synuclein in vivo. J Biol Chem (2010) 1.82
Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci (2003) 1.80
Age-related irreversible progressive nigrostriatal dopaminergic neurotoxicity in the paraquat and maneb model of the Parkinson's disease phenotype. Eur J Neurosci (2003) 1.77
Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem (2005) 1.59
Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol (2002) 1.51
Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiol Dis (2006) 1.43
Mechanistic approaches to Parkinson's disease pathogenesis. Brain Pathol (2002) 1.39
MAO-B elevation in mouse brain astrocytes results in Parkinson's pathology. PLoS One (2008) 1.39
Nuclear localization of alpha-synuclein and its interaction with histones. Biochemistry (2003) 1.33
Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res (2005) 1.27
Dieldrin exposure induces oxidative damage in the mouse nigrostriatal dopamine system. Exp Neurol (2007) 1.24
The etiopathogenesis of Parkinson disease and suggestions for future research. Part I. J Neuropathol Exp Neurol (2007) 1.21
Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol (2004) 1.20
Macrophage antigen complex-1 mediates reactive microgliosis and progressive dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. J Immunol (2008) 1.18
Increased murine neonatal iron intake results in Parkinson-like neurodegeneration with age. Neurobiol Aging (2006) 1.18
Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J (2004) 1.13
Serine 129 phosphorylation reduces the ability of alpha-synuclein to regulate tyrosine hydroxylase and protein phosphatase 2A in vitro and in vivo. J Biol Chem (2010) 1.11
Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One (2010) 1.08
Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J Biol Chem (2006) 1.06
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem (2006) 1.06
Gene-environment interactions in Parkinson's disease and other forms of parkinsonism. Neurotoxicology (2010) 1.06
Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med (2013) 1.02
Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J Neuropathol Exp Neurol (2008) 1.01
Paraquat neurotoxicity is mediated by a Bak-dependent mechanism. J Biol Chem (2007) 1.00
Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis (2005) 1.00
Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem (2003) 1.00
The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods (2005) 0.96
Lack of nigrostriatal pathology in a rat model of proteasome inhibition. Ann Neurol (2006) 0.95
Nicotine partially protects against paraquat-induced nigrostriatal damage in mice; link to alpha6beta2* nAChRs. J Neurochem (2007) 0.94
Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies. J Neurochem (2013) 0.93
Toxicity of redox cycling pesticides in primary mesencephalic cultures. Antioxid Redox Signal (2005) 0.90
Methionine oxidation stabilizes non-toxic oligomers of alpha-synuclein through strengthening the auto-inhibitory intra-molecular long-range interactions. Biochim Biophys Acta (2009) 0.90
Effect of the D3 dopamine receptor partial agonist BP897 [N-[4-(4-(2-methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on L-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther (2004) 0.87
Decreased alpha-synuclein expression in the aging mouse substantia nigra. Exp Neurol (2009) 0.87
Restorative effects of platelet derived growth factor-BB in rodent models of Parkinson's disease. J Parkinsons Dis (2011) 0.86
The etiopathogenesis of Parkinson disease and suggestions for future research. Part II. J Neuropathol Exp Neurol (2007) 0.86
Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol (2006) 0.86
Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury. Acta Neuropathol Commun (2015) 0.84
Enhanced alpha-synuclein expression in human neurodegenerative diseases: pathogenetic and therapeutic implications. Curr Protein Pept Sci (2009) 0.84
Nigrostriatal dopaminergic neurodegeneration in the weaver mouse is mediated via neuroinflammation and alleviated by minocycline administration. J Neurosci (2006) 0.83
The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Exp Neurol (2007) 0.81
Paraquat exposure reduces nicotinic receptor-evoked dopamine release in monkey striatum. J Pharmacol Exp Ther (2008) 0.80
Letter regarding: "Paraquat: the red herring of Parkinson's disease research". Toxicol Sci (2007) 0.80
L-DOPA does not cause neurotoxicity in VMAT2 heterozygote knockout mice. Neurotoxicology (2002) 0.79
Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. Exp Neurol (2003) 0.77
Evidence of oxidative stress in young and aged DJ-1-deficient mice. FEBS Lett (2013) 0.76
Dyskinesias in normal squirrel monkeys induced by nomifensine and levodopa. Neuropharmacology (2005) 0.75